These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
201 related items for PubMed ID: 16269021
1. Recombinant human erythropoietin: effects on frataxin expression in vitro. Sturm B, Stupphann D, Kaun C, Boesch S, Schranzhofer M, Wojta J, Goldenberg H, Scheiber-Mojdehkar B. Eur J Clin Invest; 2005 Nov; 35(11):711-7. PubMed ID: 16269021 [Abstract] [Full Text] [Related]
2. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Sturm B, Helminger M, Steinkellner H, Heidari MM, Goldenberg H, Scheiber-Mojdehkar B. Eur J Clin Invest; 2010 Jun; 40(6):561-5. PubMed ID: 20456483 [Abstract] [Full Text] [Related]
3. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Ann Neurol; 2007 Nov; 62(5):521-4. PubMed ID: 17702040 [Abstract] [Full Text] [Related]
5. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. Auchère F, Santos R, Planamente S, Lesuisse E, Camadro JM. Hum Mol Genet; 2008 Sep 15; 17(18):2790-802. PubMed ID: 18562474 [Abstract] [Full Text] [Related]
9. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia--a dose-response trial. Nachbauer W, Hering S, Seifert M, Steinkellner H, Sturm B, Scheiber-Mojdehkar B, Reindl M, Strasak A, Poewe W, Weiss G, Boesch S. Cerebellum; 2011 Dec 15; 10(4):763-9. PubMed ID: 21597884 [Abstract] [Full Text] [Related]
12. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Puccio H, Simon D, Cossée M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M. Nat Genet; 2001 Feb 15; 27(2):181-6. PubMed ID: 11175786 [Abstract] [Full Text] [Related]
13. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, Poewe W. Mov Disord; 2008 Oct 15; 23(13):1940-4. PubMed ID: 18759345 [Abstract] [Full Text] [Related]
14. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, Ioannou PA. J Gene Med; 2003 Jan 15; 5(1):72-81. PubMed ID: 12516053 [Abstract] [Full Text] [Related]
15. Friedreich ataxia: the oxidative stress paradox. Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, Golik P, Procaccio V, Patel M, Drapier JC, Koenig M, Puccio H. Hum Mol Genet; 2005 Feb 15; 14(4):463-74. PubMed ID: 15615771 [Abstract] [Full Text] [Related]
17. The in vivo mitochondrial two-step maturation of human frataxin. Schmucker S, Argentini M, Carelle-Calmels N, Martelli A, Puccio H. Hum Mol Genet; 2008 Nov 15; 17(22):3521-31. PubMed ID: 18725397 [Abstract] [Full Text] [Related]